Worst of Both Worlds: FDA’s Funding Structure, Corporate Capture, and Political Interference
By Danny Finley,
Bill of Health
| 01. 08. 2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application for products requiring FDA approval like prescription drugs and medical devices.
Does this non-governmental funding source insulate the FDA from political interference? No, the structure instead harms the agency by opening it up to corporate capture, while still leaving it susceptible to executive overreach and other political harms. Such political and industry pressures have led to FDA approval even when drugs lack efficacy data or fail to meet clinical trial endpoints. Ultimately, this problem is not just about how to fund an agency; it could mean the drugs you take are unsafe or ineffective despite FDA approval.
The user fees are a relatively recent phenomenon dating back just to the ’90s. During the H.W. Bush Administration’s push for fiscal responsibility, Congress looked for ways to raise revenue and expedite the FDA review process in response to industry concerns...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 09.29.2026
Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...
Artificial Intelligence (AI) has been a major focus of news recently, as it should have been, under the appropriately ridiculous name of Hugging Face, “a leading collaboration platform and community hub for machine learning, artificial intelligence, and data science.” In July, Hugging Face was hacked. The platform itself responded:
Earlier this week, we detected and responded to an intrusion into part of our production infrastructure. This one was different from anything we had handled before in one important way...
By Miryam Naddaf, Nature | 09.21.2026
A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently...
By Karen Weintraub, Endpoints News | 09.16.2026
To better understand certain neuropsychiatric disorders, researchers at Stanford University have bred rodents that lack a cortex and hippocampus and then replaced those missing brain cells with human ones.
The altered mice, a scientific first, provided insights that would not...